Microtissues, Inc.
Since 2010, Microtissues, Inc has been selling the 3D PetriDish, a reusable micro-mold platform system for forming multi-cellular spheroids and organoids from primary cells, cancer cells, stem cells and cell lines. Our products are distributed worldwide by Millipore Sigma and have been used in over 200 peer-reviewed publications, a list which is available on our website.
Potentiating NaV1.1 in Dravet syndrome patient iPSC-derived GABAergic neurons increases neuronal firing frequency and decreases network synchrony
Modeling neurodegenerative diseases using in vitro compartmentalized microfluidic devices
Bioprinting Laboratories
Bioprinting Labs’ pillar/perfusion plates enable robust and reproducible organoid culture and in situ analysis. Our products streamline organoid-based assays by facilitating miniature organoid culture and enhancing organoid maturity through dynamic culture in the pillar/perfusion plates.
AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Axol BioScience
Axol Bioscience are leaders in human iPSC products and services for CNS, PNS and cardiac research. Under ISO9001, we manufacture functional hiPSC-derived cells with multi-platform utility for MPS technology, alongside a “one-stop shop” of iPSC lines, services and custom assays.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
MEPSGEN
Advanced microfluidic technologies for Nanomedicine Development. We develop and employ human microphysiological systems or organ-on-a-chip to better predict drug toxicity and efficacy.